§ Claim under review · Health
"28 mg of saffron extract (Affron) taken daily for 3 months (12 weeks) significantly improved depressive symptoms in adults with subclinical depression compared to placebo"
Verdict
Accurate
Confidence
HighSummary
This claim accurately reports a real study. The trial cited (PMID 40414301, published in The Journal of Nutrition in 2025) did randomly assign 202 adults aged 18 to 70 with mild, below-diagnostic depressive symptoms to 28 mg per day of the saffron extract Affron or placebo for 12 weeks, and the saffron group showed a statistically greater improvement in self-reported depression scores, a difference of 2.92 points, with 72.3% classed as responders versus 54.3% on placebo. The important context the post leaves out is that the study was funded by Pharmactive, the company that makes Affron, which was also involved in designing the study, and that the lead author runs a research organization funded by supplement companies. The effect size was small to moderate and measured by questionnaire, and more than half the placebo group also improved, which the study authors themselves flagged as a limitation. The sleep benefit came from an exploratory analysis of one subgroup, and most other secondary outcomes showed no difference. This is one trial in people without diagnosed depression, so it does not show that saffron treats clinical depression. Independent replication by researchers with no commercial ties would strengthen the finding considerably.
The readings
key figures from the evidenceDASS-21 depression score difference vs placebo
saffron group achieving clinically significant response
placebo group achieving clinically significant response
Why this verdict
Evidence
The cited paper exists and matches the PMID given. The trial was a 2-arm, 12-week, parallel-group, randomized, double-blind, placebo-controlled study examining a saffron extract (Affron) on mood and sleep in adults with subclinical depressive symptoms, in which 202 adults aged 18 to 70 with depressive symptoms received 28 mg saffron daily or placebo.
On the primary outcome measure, compared to placebo, saffron was associated with greater improvements in the DASS-21 depression score (beta: -2.92 points; 95% CI: -5.13, -0.71; Cohen's d = 0.39), with 72.3% of participants in the saffron group achieving a clinically significant change (a reduction of at least 7 points) compared with 54.3% of participants in the placebo group.
Exploratory analyses across various strata and assumptions identified improvements in sleep disturbances (beta: -2.72 points; 95% CI: -4.99, -0.46; Cohen's d = 0.44) in a subset of participants with greater severity of sleep disturbance, and no serious adverse reactions were reported.
The authors concluded the study, described as the largest conducted to date on saffron, supports beneficial effects of 3 months of saffron supplementation on depressive symptoms in adults, while noting that large placebo responses were evident and require consideration in future trials.
The abstract also states that in the other secondary outcomes there was no evidence of between-group differences.
Findings
✓ What's accurate 5
- The cited study exists, and PMID 40414301 matches the paper described.
- The dose (28 mg/day), duration (12 weeks), design (randomized, double-blind, placebo-controlled), sample (202 adults aged 18 to 70), and population (subclinical depressive symptoms) are all stated accurately.
- The 2.92-point between-group difference, the 72.3% versus 54.3% responder figures, and the at least 7-point responder threshold are reproduced accurately from the abstract.
- The statement that the improvement was statistically significant is supported: the confidence interval excludes zero.
- The caption's additional statements are also accurate: the sleep benefit appeared in a subgroup with greater sleep disturbance, most other secondary outcomes showed no between-group difference, and no serious adverse reactions were reported.
≈ What's misleading 5
- Nothing in the claim contradicts the source. The issues are omissions of context rather than misstatements:
- Omitted qualifier (funding and conflict of interest): the post does not disclose that the trial was funded by Pharmactive, the manufacturer of Affron, which was involved in study design, or that the lead author runs a contract research organization funded by nutraceutical companies. For a branded-ingredient claim, this is material.
- Omitted qualifier (placebo response): the post reports 54.3% placebo response but does not flag that the authors themselves highlighted large placebo responses as a limitation requiring consideration in future trials. The headline 72.3% figure reads as a saffron effect when the majority of that improvement also occurred on placebo.
- Omitted qualifier (effect magnitude): "significantly improved" is statistically correct but the effect was small to moderate (d = 0.39) on a self-report scale, with a wide confidence interval whose upper bound approaches negligible benefit. Statistical significance is not the same as a noticeable real-world change.
- Scope: this is a single trial in people with subclinical symptoms. It does not speak to treatment of diagnosed major depressive disorder, and the post's framing does not make that boundary explicit beyond the word "subclinical."
? What's uncertain 4
- I retrieved the abstract and funding statements but not the full text, so per-arm baseline scores, dropout and attrition handling, blinding integrity checks, and the full pre-specified analysis plan were not verified.
- I did not retrieve the ANZCTR registry entry itself, so I could not independently confirm that the DASS-21 depression score was pre-registered as the primary outcome or whether the responder threshold was pre-specified.
- Whether the sleep subgroup analysis was pre-specified or purely post hoc is not resolvable from the abstract, which labels it exploratory.
- Replication status is unclear. A separate, smaller Affron trial in 86 women aged 50 to 70 reported a similar direction of effect, but it is also manufacturer-funded and from the same research group, so it is not independent replication.
Sources
6 of 6 linked to recordsLopresti AL, Smith SJ, Marx W, Diez-Municio M, Moran-Valero MI. "An Examination into the Effects of a Saffron Extract (Affron) on Mood and General Wellbeing in Adults Experiencing Low Mood: A Randomized, Double-Blind, Placebo-Controlled Trial." J Nutr. 2025 Jul;155(7):2300-2311. doi:10.1016/j.tjnut.2025.05.024. PMID 40414301
Bond University Research Portal record with full structured abstract
ScienceDirect record including funding and conflict statements
Marion Nestle, Food Politics, "Industry-funded study of the week: Saffron and Mood"
NutraIngredients trade coverage
Nutritional Outlook trade coverage